Thrivent Financial for Lutherans Sells 139,382 Shares of RxSight, Inc. $RXST

Thrivent Financial for Lutherans lessened its holdings in shares of RxSight, Inc. (NASDAQ:RXST) by 30.9% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 312,220 shares of the company’s stock after selling 139,382 shares during the quarter. Thrivent Financial for Lutherans’ holdings in RxSight were worth $4,059,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of RXST. Raymond James Financial Inc. bought a new stake in shares of RxSight during the 2nd quarter worth approximately $28,000. Bessemer Group Inc. bought a new stake in shares of RxSight during the second quarter worth $33,000. State of Wyoming lifted its position in shares of RxSight by 91.5% during the first quarter. State of Wyoming now owns 2,062 shares of the company’s stock worth $52,000 after purchasing an additional 985 shares during the last quarter. CWM LLC boosted its stake in shares of RxSight by 614.1% during the second quarter. CWM LLC now owns 4,520 shares of the company’s stock valued at $59,000 after purchasing an additional 3,887 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of RxSight by 156.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after purchasing an additional 3,398 shares during the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

RxSight Stock Performance

Shares of RXST opened at $12.03 on Friday. The company has a 50 day moving average price of $10.18 and a 200-day moving average price of $9.99. RxSight, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $37.13. The stock has a market capitalization of $494.67 million, a PE ratio of -13.67 and a beta of 1.14.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.15. The company had revenue of $30.34 million for the quarter, compared to analyst estimates of $25.63 million. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. RxSight’s revenue was down 31.4% compared to the same quarter last year. During the same period last year, the company posted ($0.16) earnings per share. Equities research analysts forecast that RxSight, Inc. will post -0.7 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RXST. Zacks Research upgraded shares of RxSight from a “strong sell” rating to a “hold” rating in a report on Monday, September 8th. Morgan Stanley raised their target price on shares of RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Needham & Company LLC lifted their price target on shares of RxSight from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Wells Fargo & Company increased their price objective on RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of RxSight in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $9.67.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.